noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

U.S. Senate Committee on Energy[...]

ICYMI: Heinrich and Whitehouse Host Roundtable on Skyrocketing Energy[...]
Hermeus Corp.

Welcome to Atlanta's Newest Airplane Factory
Hermeus Corp.

Hermeus Fully-Funded to Flight with $60 Million U.S. Air Force Partnership

Healthcare

Headlands Research Inc.

07/01/2025 | Press release | Archived content

Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy

A new once-weekly insulin, efsitora, may be just as effective as daily injections for adults with type 2 diabetes who are new to insulin therapy. In a 52-week clinical trial, efsitora matched the performance of daily insulin glargine in lowering blood sugar, with fewer dose adjustments and a lower risk of severe hypoglycemia.

Dr. Timothy Bailey, Founder and Site President at Headlands Research - AMCR Institute, co-authored the study.

Headlands Research Inc. published this content on July 01, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 18, 2026 at 04:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format